PDCD1 and neoplasm: Notably, our subgroup analyses found that TACE+DP treatment was associated with favorable PFS versus TACE+D in patients with a significant tumor burden, such as portal vein invasion Vp3-4, maximum tumor diameter >10 cm, and three or more intrahepatic tumors, supporting the hypothesis that a low tumor burden after TACE might improve the efficacy of donafenib and PD-1 inhibitors.